(NASDAQ: CRDL) Cardiol Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 7.02%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.79%.
Cardiol Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast CRDL's revenue for 2027 to be $2,852,804,617, with the lowest CRDL revenue forecast at $2,852,804,617, and the highest CRDL revenue forecast at $2,852,804,617. On average, 1 Wall Street analysts forecast CRDL's revenue for 2028 to be $8,156,887,217, with the lowest CRDL revenue forecast at $8,156,887,217, and the highest CRDL revenue forecast at $8,156,887,217.
In 2029, CRDL is forecast to generate $11,047,598,194 in revenue, with the lowest revenue forecast at $11,047,598,194 and the highest revenue forecast at $11,047,598,194.